Teva Pharms Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for TEVA PHARMS INC, and when can generic versions of TEVA PHARMS INC drugs launch?
TEVA PHARMS INC has eight approved drugs.
There is one US patent protecting TEVA PHARMS INC drugs. There are two tentative approvals on TEVA PHARMS INC drugs.
There are two patent family members on TEVA PHARMS INC drugs in two countries and fifty-one supplementary protection certificates in sixteen countries.
Summary for Teva Pharms Inc
| International Patents: | 2 |
| US Patents: | 1 |
| Tradenames: | 8 |
| Ingredients: | 8 |
| NDAs: | 8 |
Drugs and US Patents for Teva Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Pharms Inc | THEOPHYLLINE | theophylline | TABLET, EXTENDED RELEASE;ORAL | 216961-001 | Oct 12, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Teva Pharms Inc | ALVAIZ | eltrombopag choline | TABLET;ORAL | 216774-001 | Nov 29, 2023 | RX | Yes | No | 11,072,586 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Teva Pharms Inc | CETRORELIX ACETATE | cetrorelix acetate | POWDER;SUBCUTANEOUS | 215737-001 | Aug 12, 2022 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Teva Pharms Inc Drugs
Supplementary Protection Certificates for Teva Pharms Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1294378 | 91681 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: ELTROMBOPAG, EVENTUELLEMENT SOUS FORME D'UN SEL OU D'UN SOLVATE (Y COMPRIS SOUS FORME D'UN HYDRATE) PHARMACEUTIQUEMENT ACCEPTABLE (REVOLADE ); AUTHORISATION NUMBER AND DATE: EU/1/10/612/001-006 - REVOLADE-ELTROMBOPAG 20100315 |
| 2101777 | 2016C/032 | Belgium | ⤷ Sign Up | PRODUCT NAME: AMBRISENTAN EN COMBINAISON AVEC LE TADALAFIL; AUTHORISATION NUMBER AND DATE: EU/1/08/451 20151125 |
| 1853250 | 2014C/037 | Belgium | ⤷ Sign Up | PRODUCT NAME: PACLITAXEL DANS UNE FORMULATION DE NANOPARTICULE LIEES A L'ALBUMINE; AUTHORISATION NUMBER AND DATE: EU/1/07/428 20131230 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
